Trial Profile
A Pilot Study of Nintedanib in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 23 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 15 Sep 2023 Planned End Date changed from 30 Jun 2023 to 31 Dec 2023.
- 03 Jan 2023 Planned End Date changed from 31 Dec 2022 to 30 Jun 2023.